Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Anas Najjar & Rafik Karaman. (2019) Successes, failures, and future prospects of prodrugs and their clinical impact. Expert Opinion on Drug Discovery 14:3, pages 199-220.
Read now
Read now
Nellowe Candelario & Marvin Louis Roy Lu. (2016) Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives. Cancer Management and Research 8, pages 77-82.
Read now
Read now
Luigi Celio, Francesca Ricchini & Filippo De Braud. (2013) Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. Patient Preference and Adherence 7, pages 391-400.
Read now
Read now
Articles from other publishers (20)
Rajesh Kumar, Charanjit Kaur, Kawalpreet Kaur, Navneet Khurana & Gurvinder Singh. (2023) Prodrugs: Harnessing chemical modifications for improved therapeutics. Journal of Drug Delivery Science and Technology 90, pages 105103.
Crossref
Crossref
Qingshan Huang, Fan Wang, Chujun Liang, Yabin Huang, Yingyin Zhao, Chuling Liu, Chunmeng Lin, Lizhen Zhang, Shaoli Zhou, Qiuling Wang, Shan Li, Ruirui Gong, Qian Wu, Yuting Gu, Jinxin Zhang, Tongfeng Luo, Wei Wang, Song Zhang, Nassirou Bizo Mailoga, Kai Wang, Sanqing Jin & Yang Zhao. (2023) Fosaprepitant for postoperative nausea and vomiting in patients undergoing laparoscopic gastrointestinal surgery: a randomised trial. British Journal of Anaesthesia.
Crossref
Crossref
Nikolai A. Ognerubov. (2023) Fosaprepitant: current options to prevent chemotherapy-induced nausea and vomiting: A review. Journal of Modern Oncology 24:4, pages 477-486.
Crossref
Crossref
Jinqian Liu, Wen Wang, Changqing Wang, Li Zhang, Xueliang Zhang, Shicong Liu, Yunhua Xu, Hailin Wang, Qing Dai, Chun Liu, Xinghai Wang, Zhengyu Yuan & Mikhail F. Gordeev. (2022)
Discovery of Antibacterial Contezolid Acefosamil: Innovative
O
-Acyl Phosphoramidate Prodrug for IV and Oral Therapies
. ACS Medicinal Chemistry Letters 13:7, pages 1030-1035.
Crossref
Crossref
Xinglu Xu, Yuwen Bao, Kai Xu, Zhuolin Zhang, Ningli Zhao & Xin Li. (2022) Economic Value of Fosaprepitant-Containing Regimen in the Prevention of Chemotherapy-Induced Nausea and Vomiting in China: Cost-Effectiveness and Budget Impact Analysis. Frontiers in Public Health 10.
Crossref
Crossref
Zhaosheng Jin, Neil Daksla & Tong J. Gan. (2021) Neurokinin-1 Antagonists for Postoperative Nausea and Vomiting. Drugs 81:10, pages 1171-1179.
Crossref
Crossref
Kang Lu, Sisi Lin, Yannan Wang, Rui Hao, Lu Fang, Jingjing Zhu, Di Zhao, Jin Yu, Shengjia Tong, Yi Wu, Yongkai Si, Tiantian Ye, Qigang Yang & Ying Wang. (2020) Pharmacokinetics and Safety of Fosaprepitant Dimeglumine in Healthy Chinese Volunteers: Bioequivalence Study. Clinical Pharmacology in Drug Development 10:7, pages 748-755.
Crossref
Crossref
Anne Chain, Rebecca Wrishko, Grygoriy Vasilinin & Samer Mouksassi. (2020) Modeling and Simulation Analysis of Aprepitant Pharmacokinetics in Pediatric Patients With Postoperative or Chemotherapy-Induced Nausea and Vomiting. The Journal of Pediatric Pharmacology and Therapeutics 25:6, pages 528-539.
Crossref
Crossref
Anas Najjar, Abderrahman Najjar & Rafik Karaman. (2020) Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years. Molecules 25:4, pages 884.
Crossref
Crossref
JALIL K. SHAIKH, MAZAHAR FAROOQUI & UMMUL KHAIR ASEMA SYED. (2020) Quality by Design Approach for Development and Validation of
Stability Indicating RP-HPLC Method for Fosaprepitant Dimeglumine. Asian Journal of Chemistry 32:9, pages 2158-2164.
Crossref
Crossref
Jaume Mora, Miguel Valero, Cara DiCristina, Mandy Jin, Anne Chain & Kara Bickham. (2019) Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy‐induced nausea and vomiting in pediatric cancer patients. Pediatric Blood & Cancer 66:6, pages e27690.
Crossref
Crossref
Venkatraman Radhakrishnan. (2021) Drug review: Fosaprepitant. Indian Journal of Medical and Paediatric Oncology 40:01, pages 132-135.
Crossref
Crossref
Motoki Urata, Yuki Narita, Masaki Fukunaga, Daisuke Kadowaki & Sumio Hirata. (2018) Simple Formula for Predicting Drug Removal Rates During Hemodialysis. Therapeutic Apheresis and Dialysis 22:5, pages 485-493.
Crossref
Crossref
Jun Atsuta, Satoki Inoue, Yuu Tanaka, Keiko Abe, Hiroyuki Nakase & Masahiko Kawaguchi. (2016) Fosaprepitant versus droperidol for prevention of PONV in craniotomy: a randomized double-blind study. Journal of Anesthesia 31:1, pages 82-88.
Crossref
Crossref
Anton G. Henssen, Andrea Odersky, Annabell Szymansky, Marleen Seiler, Kristina Althoff, Anneleen Beckers, Frank Speleman, Simon Schäfers, Katleen De Preter, Kathy Astrahanseff, Joachim Struck, Alexander Schramm, Angelika Eggert, Andreas Bergmann & Johannes H. Schulte. (2016) Targeting tachykinin receptors in neuroblastoma. Oncotarget 8:1, pages 430-443.
Crossref
Crossref
. 2016. Bio-Targets and Drug Delivery Approaches. Bio-Targets and Drug Delivery Approaches
77
104
.
Wendy Pritchett & Karen Kinsley. (2016) Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens. Clinical Journal of Oncology Nursing 20:5, pages 555-556.
Crossref
Crossref
Qi Shi, Wen Li, Hongjia Li, Qiqi Le, Shanshan Liu, Shaoqi Zong, Leizhen Zheng & Fenggang Hou. (2016) Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison. Oncotarget 7:17, pages 24402-24414.
Crossref
Crossref
Henrik KehletLinda M.L. Lai, William K.K. Wu & Matthew T.V. Chan. 2016. Postoperative Nausea and Vomiting. Postoperative Nausea and Vomiting
74
89
.
Bernardo Rapoport, Daniel Chua, Allen Poma, Sujata Arora, Yan Wang & Luis Enrique Fein. (2015) Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Supportive Care in Cancer 23:11, pages 3281-3288.
Crossref
Crossref